Geron Corp. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp.

GERN 1.200

+2.6%

Dec 1 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: BulbaMan who started this subject	6/15/2003 10:17:41 PM
From: mopgcw	of 3576

From Barron's: Geron (GERN-NYSE) by Rodman & Renshaw (5.87, June 9) We are initiating coverage with a Market Outperform/Speculative Risk rating and a 12-month target price of $9...Geron's most advanced product is a cancer vaccine targeting telomerase, a protein specific to cancer cells. Phase I/II clinical trials have shown strong preliminary safety and efficacy results in hormone refractory metastatic prostate cancer patients...Geron is the leader in the development of stem-cell therapeutics for long-term treatment and potential cure of neurodegenerative disease, spinal cord injury, diabetes, heart failure and osteoporosis.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next